2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1317

Do Patients with MRSA-Positive Septic Arthritis Differ Clinically from Non-MRSA-Positive Counterparts?
Abstract Number: 1318

Profile of Macrophage-Derived Cytokines and Chemokines of Patients with Chikungunya-Induced Chronic Arthralgia/Arthritis
Abstract Number: 1319

Chikungunya Fever in Patients on Biological and on Conventional Dmards Therapy – Results from the Brazilian Register Biobadabrasil
Abstract Number: 1320

Chikungunya Fever Outbreak in Brazil: Preliminary Assessment in a Cohort of Patients with Rheumatological Manifestations
Abstract Number: 1321

Distinguishing Features of Polymicrobial Septic Arthritis
Abstract Number: 1322

Use of Biologics in Arthritis Patients with Hepatitis B and C ‏: A Multicentral Retrospective Case Series
Abstract Number: 1323

Systemic Manifestations Associated with Parvovirus B19 Infection in Adults: A Retrospective Study in 23 Patients
Abstract Number: 1324

The Result of Follow-up Interferon-Gamma-Release Assays in Patients with Rheumatic Disease Receiving Biologic Agents in a Japanese Hospital
Abstract Number: 1325

Musculoskeletal Manifestations in Ebola Survivors
Abstract Number: 1326

Autoimmune Arthritides, Rheumatoid Arthritis, Psoriatic Arthritis, or Peripheral Spondyloarthropathy, Following Lyme Disease
Abstract Number: 1327

Patients with Chikungunya Fever Have Increased Serum Levels of Proinflamatory Cytokines
Abstract Number: 1328

Infective Endocarditis with Septic Arthritis: A Single-Center Experience
Abstract Number: 1329

Efficacy and Safety of Biologics in Relapsing Polychondritis: A National Multicenter Study in France
Abstract Number: 1330

Clinical Presentations of Relapsing Polychondritis: More Than a Swollen Ear
Abstract Number: 1331

Disease Patterns and Long Term Outcome Amongst Patients with Relapsing Polychondritis – Single Centre Experience

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].